New drug tested in race to slow devastating ALS
NCT ID NCT05842941
Summary
This study tested an investigational drug called DNL343 to see if it could slow the progression of ALS and improve survival. It involved 249 people with ALS who were randomly assigned to receive either the active drug or a placebo for 24 weeks. The main goals were to measure changes in physical function and the rate of death or need for permanent breathing assistance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Healey Center for ALS at Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.